By Fineline Cube 
Germany-based BioNTech SE (NASDAQ: BNTX) announced plans to acquire all outstanding shares of fellow German biotech company CureVac N.V. (NASDAQ: CVAC) for USD 1.25 billion. This strategic move aims to bolster BioNTech’s capabilities in researching, developing, producing, and commercializing mRNA-based cancer immunotherapies.
Strategic Rationale
The acquisition will enhance BioNTech’s existing expertise in mRNA design, delivery formulations, and manufacturing. It aligns with BioNTech’s oncology strategy, which centers on advancing mRNA-based cancer immunotherapy candidates and BNT327, a PD-L1×VEGF-A bispecific antibody.-Fineline Info & Tech